Zymeworks Inc. (ZYME) Posts Phase 1 ZW191 Data Showing High Responses, Better Tolerability at 6.4 mg/kg

Zymeworks Inc. (ZYME) reported Phase 1 data for ZW191, showing 64.5% objective response rate at 6.4 mg/kg in platinum-resistant ovarian cancer. The treatment demonstrated favorable tolerability and activity across FRα expression levels. A conference call is scheduled for October 27.

Original reporting
Published Oct 24, 2026, 6:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 24, 2026, 6:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Zymeworks Inc. (ZYME) Posts Phase 1 ZW191 Data Showing High Responses, Better Tolerability at 6.4 mg/kg — source image
Decision brief

The 30-second read

$ZYMEBullishMed
01

Why it matters

The data provides a clear dose‑selection signal and may accelerate partnership talks, influencing the stock price.

02

Market read

New trial data is a material catalyst for Zymeworks and could affect related ADC stocks.

03

What to watch

Future dosing strategy and regulatory pathway remain uncertain; partnership terms will drive valuation.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Zymeworks released its first‑in‑human Phase 1 results for ADC ZW191 targeting folate‑receptor alpha in heavily pretreated, platinum‑resistant ovarian cancer patients.

Company-level read

Ticker impact

$ZYMEBullishHigh confidence
Context

Phase 1 data shows 64.5% cORR at 6.4 mg/kg in platinum‑resistant ovarian cancer, with lower grade ≥3 AEs versus higher dose.

Expected impact

likely upside as investors price in favorable trial results and potential partnership upside

Evidence & confidence

Phase 1 data is a primary disclosure for a biotech; high response rates and better safety are material catalysts.

Market effects

May boost sentiment for ADC and ovarian‑cancer biotech peers.

North American biotech sector could see modest gains.

Limited to biotech investors; no broad market effect.

Counterpoint

Phase 1 data may be early; efficacy could wane in later trials, so caution is warranted.

Key entities

  • Zymeworks Inc.

    Biotech developing antibody‑drug conjugates, ticker ZYME.

Related articles

$ZYMEHighAI 9/10

Zymeworks Inc. (ZYME): Reports Third Quarter 2026 Financial Results

Zymeworks Inc. (ZYME) filed an SEC Form 8-K — Results of Operations and Financial Condition. Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results • 2026 financial guidance raised to a total revenue range of $337 million to $351 million (previously between $278 million and $292 million) and an Adjusted EBITDA range of $176 million to $190 m

$ZYMEMedAI 8/10

Zymeworks (ZYME) Gains Fresh Backing On Trial Data And Roche Deal

Zymeworks (ZYME) gained attention due to Phase 1 trial data for ZW191 in ovarian cancer and a licensing deal with Roche for ZW209. The stock has seen significant returns: 19.8% in 1 month, 28.2% in 3 months, 65.9% in 1 year, and 4x in 3 years. Analysts debate its valuation, with some seeing it as 27% undervalued at a fair value of $41.50, while others note its high P/B ratio of 26.6x compared to peers.

$ZYMEMedAI 9/10

Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside

Zymeworks presented updated trial results for ZW191, an ovarian cancer treatment, showing 65% and 55% response rates at 6.4 mg/kg and 9.6 mg/kg doses, respectively. The company plans to seek external funding for further development. Zymeworks also highlighted positive data from a partner's study of Ziihera in gastroesophageal cancer. Management discussed strategic plans for R&D, partnerships, and capital allocation.

$ZYMEMed

Truist raises Zymeworks stock price target on pipeline progress

Truist Securities raised its price target for Zymeworks Inc. (NASDAQ:ZYME) to $35, citing pipeline progress and partnerships. The stock is up 53.6% over the past year, with a consensus Buy rating and 46% upside potential. Zymeworks recently acquired Theravance Biopharma and partnered with Roche for ZW209, with analysts highlighting positive developments and raising price targets.